497 related articles for article (PubMed ID: 15734073)
1. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
Berthold I; Pombo ML; Wagner L; Arciniega JL
Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
[TBL] [Abstract][Full Text] [Related]
2. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
[TBL] [Abstract][Full Text] [Related]
3. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.
Jendrek S; Little SF; Hem S; Mitra G; Giardina S
Vaccine; 2003 Jun; 21(21-22):3011-8. PubMed ID: 12798645
[TBL] [Abstract][Full Text] [Related]
5. Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.
Domínguez-Castillo RI; Verma A; Amador-Molina JC; Sirota L; Arciniega JL
Biologicals; 2013 Mar; 41(2):111-4. PubMed ID: 23137818
[TBL] [Abstract][Full Text] [Related]
6. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.
Ribot WJ; Powell BS; Ivins BE; Little SF; Johnson WM; Hoover TA; Norris SL; Adamovicz JJ; Friedlander AM; Andrews GP
Vaccine; 2006 Apr; 24(17):3469-76. PubMed ID: 16519970
[TBL] [Abstract][Full Text] [Related]
7. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
[TBL] [Abstract][Full Text] [Related]
8. Development of an in vitro-based potency assay for anthrax vaccine.
Little SF; Webster WM; Ivins BE; Fellows PF; Norris SL; Andrews GP
Vaccine; 2004 Jul; 22(21-22):2843-52. PubMed ID: 15246620
[TBL] [Abstract][Full Text] [Related]
9. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants.
Romero Méndez IZ; Shi Y; HogenEsch H; Hem SL
Vaccine; 2007 Jan; 25(5):825-33. PubMed ID: 17014935
[TBL] [Abstract][Full Text] [Related]
12. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.
Little SF; Ivins BE; Webster WM; Fellows PF; Pitt ML; Norris SL; Andrews GP
Vaccine; 2006 Mar; 24(14):2530-6. PubMed ID: 16417950
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
[TBL] [Abstract][Full Text] [Related]
14. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.
Little SF; Ivins BE; Fellows PF; Pitt ML; Norris SL; Andrews GP
Vaccine; 2004 Jan; 22(3-4):422-30. PubMed ID: 14670324
[TBL] [Abstract][Full Text] [Related]
15. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
16. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
Sloat BR; Cui Z
Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
[TBL] [Abstract][Full Text] [Related]
17. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
Oscherwitz J; Yu F; Cease KB
J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
Sloat BR; Cui Z
J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
[TBL] [Abstract][Full Text] [Related]
20. Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.
Wagner L; Verma A; Meade BD; Reiter K; Narum DL; Brady RA; Little SF; Burns DL
Clin Vaccine Immunol; 2012 Sep; 19(9):1465-73. PubMed ID: 22815152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
